Nasdaq: ORKA+12.99% 24h move
Price before$69.03Apr 24, 2026, 4:00 PM ET
First trade after$83.99Apr 27, 2026, 8:01 AM ET
24h later$78.00Apr 28, 2026, 7:44 AM ET
Complete Announced during: Premarket · announced Mon 8:00a ET (premarket); before = Fri close; first trade Mon 8:01a ET; time = SEC 8-K acceptance
Oruka Therapeutics (Nasdaq: ORKA) reported results from a Phase 2 trial of ORKA-001 on April 27, 2026. The company said the trial met its primary endpoint.
Trial details
- Drug
- ORKA-001
- Treats
- Plaque Psoriasis
- Phase
- Phase 2
- Result
- Met endpointEfficacy 40 of 63 participants (63.5%) treated with ORKA-001 achieved the primary endpoint of PASI 100 at Week 16, representing complete skin clearance.
- Safety
- “If this type of efficacy and safety profile could be available with dosing once to twice per year, it would represent a major step forward for the field.
- Sponsor
- Oruka Therapeutics Nasdaq: ORKA
- Dates
- Announced Apr 27, 2026, 8:00 AM ET (SEC 8-K filing time)
About this trial
This Phase 2 trial tested ORKA-001 in Plaque Psoriasis. Oruka Therapeutics reported that the trial met its primary endpoint.
Sources
- Source: SEC EDGAR 8-K (EX-99.1)
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.